{"schema_version":"secwatch.filing_event.v1","accession":"0001001233-25-000023","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.448665+00:00","generated_at":"2026-05-16T23:17:07.298248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo Q3 net loss $34.9M, revenue $0.6M; advancing Fabry BLA and pain trial enrollment","bullets":["Q3 2025 consolidated net loss $34.9M ($0.11/sh) vs net income $10.7M ($0.04/sh) in prior year.","Revenue of $0.6M down from $49.4M, mainly due to absence of Genentech collaboration revenue.","Cash and equivalents $29.6M; with Pfizer $6M license fee and ATM proceeds, runway into Q1 2026.","FDA reiterated eGFR slope endpoint for isaralgagene civaparvovec accelerated approval; BLA submission expected as early as Q1 2026.","First two clinical sites activated for Phase 1/2 ST-503 chronic neuropathic pain study; first patient dosing expected in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001001233-25-000023","json":"https://secwatch.observer/filing/0001001233-25-000023.json","markdown":"https://secwatch.observer/filing/0001001233-25-000023.md","text":"https://secwatch.observer/filing/0001001233-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/0001001233-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000100123325000023/sgmo-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:17:07.298248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}